Premium
Mitochondria‐Targeted Antioxidants in the Treatment of Disease
Author(s) -
Smith Robin A.J.,
Adlam Victoria J.,
Blaikie Frances H.,
Manas AbdulRahman B.,
Porteous Carolyn M.,
James Andrew M.,
Ross Meredith F.,
Logan Angela,
Cochemé Helena M.,
Trnka Jan,
Prime Tracy A.,
Abakumova Irina,
Jones Bruce A.,
Filipovska Aleksandra,
Murphy Michael P.
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1427.003
Subject(s) - mitochondrion , antioxidant , oxidative phosphorylation , oxidative damage , chemistry , biochemistry , moiety , inner mitochondrial membrane , oxidative stress , programmed cell death , microbiology and biotechnology , biology , apoptosis , stereochemistry
Mitochondrial oxidative damage is thought to contribute to a wide range of human diseases; therefore, the development of approaches to decrease this damage may have therapeutic potential. Mitochondria‐targeted antioxidants that selectively block mitochondrial oxidative damage and prevent some types of cell death have been developed. These compounds contain antioxidant moieties, such as ubiquinone, tocopherol, or nitroxide, that are targeted to mitochondria by covalent attachment to a lipophilic triphenylphosphonium cation. Because of the large mitochondrial membrane potential, the cations are accumulated within the mitochondria inside cells. There, the conjugated antioxidant moiety protects mitochondria from oxidative damage. Here, we outline some of the work done to date on these compounds and how they may be developed as therapies.